Ibrutinib for Mantle Cell Lymphoma

Ibrutinib (Imbruvica) has been FDA approved for the treatment of mantle cell lymphoma who have received at least one prior therapy.

New treatment for CLL

Gazyva (obinutuzumab) now approved for use in combination with chlorambucil for previously untreated CLL patients (chronic lymphocytic leukemia).